Vivani Medical Achieves 1st Implant & Full Enrollment in Overweight Trial
By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medscape16h
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Labiotech.eu2h
Can GLP-1 agonists help treat addiction?
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
GlobalData on MSN23h
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...